COMMUNIQUÉS West-GlobeNewswire

Flyte Hops: Vision Jet Platform Seeks to Redefine Private Aviation
25/03/2026
Hops Scalable Vision Jet Fleet Expansion Unlocking High-Frequency Short-Haul Regional Travel Flyte’s Vision Jet-Powered Hops Platform Aims to Establish a New Standard in Regional Travel with Industry-Leading Safety, [...]
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
25/03/2026
FDA provided constructive feedback on Company’s analytical similarity strategy under the 351(k) biosimilar pathway Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with the [...]
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
25/03/2026
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 [...]
CDT Equity Inc. Announces Reverse Stock Split
25/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) announces that its board of directors has approved a 1-for-25 reverse stock split of [...]
Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)
25/03/2026
– TEV ‘325, which targets IL-13 and TSLP, is being studied for the treatment of TH2-driven inflammatory diseases such as asthma and atopic dermatitis – TEV ‘325 was computationally designed using Biolojic’s Multibody [...]
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
25/03/2026
Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo [...]
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
25/03/2026
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company” ), a drug [...]
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
25/03/2026
BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious [...]
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
25/03/2026
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's [...]
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue
25/03/2026
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One [...]
Cellbricks Therapeutics Raises €10 Million New Capital to Move Living Tissue Implants Toward the Clinic
25/03/2026
Funding will accelerate preclinical validation of biofabricated tissue implants for soft tissue repair, wound healing and trauma care - while building the biological and manufacturing foundations for 3D-bioprinted [...]
Verano to Report First Quarter 2026 Financial Results on April 30, 2026
25/03/2026
CHICAGO, March 25, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial [...]
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
25/03/2026
Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical [...]
Tilray Brands to Announce Third Quarter Fiscal Year 2026 Financial Results on April 1, 2026
25/03/2026
NEW YORK and LEAMINGTON, Ontario, March 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of [...]
NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
25/03/2026
The collaboration aims to uncover clinically actionable patient subpopulations and biomarker-driven treatment insights from a landmark precision-oncology trial TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark [...]
ADMA Biologics Addresses Misleading Short-Seller Report
25/03/2026
RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to [...]
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
25/03/2026
Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8: [...]
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
25/03/2026
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today [...]
Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approval
25/03/2026
Arboretum Ventures leads financing, with participation from existing investors, as Endogenex advances its novel treatment targeting a damaged duodenum as a driver of type 2 diabetes MINNEAPOLIS, March 25, 2026 (GLOBE [...]

Pages